SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We're responsible for the development of innovative next-generation drugs within SK Group. SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do. With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing. For more information, visit our website at www.skbp.com.
We're tracking SK Biopharmaceuticals's market expansion
2 signals in the last 90 days.
How SK Biopharmaceuticals's international expansion compares to its competitors
SK BiopharmaceuticalsYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 SK BiopharmaceuticalsYou | 0 | 0 | — | 0 | 0 |
RPT Business Development Manager
View postingGyeonggi, South Korea · 3w ago
Legal Counsel
View postingGyeonggi, South Korea · 3w ago
경영기획(Corp.Planning Manager)
View postingGyeonggi, South Korea · 2mo ago
No tracked technology yet
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Choi Yoon-jung, third-generation owner of SK Biopharm, takes charge of new business development, focusing on radiopharmaceuticals and targeted protein degradation.
SK Biopharm opened 'SK Life Science LinX' in New Jersey to support Korean biotech companies entering the US market with 160-pyeong facility including offices and meeting rooms.
SK Biopharm's epilepsy drug Cenobamate and sleep disorder drug Solriamfetol received approval from China's NMPA, expanding into the Chinese market.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about SK Biopharmaceuticals's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.